Nephros (NASDAQ:NEPH) Posts Quarterly Earnings Results, Meets Estimates

Nephros (NASDAQ:NEPH) posted its quarterly earnings results on Thursday. The company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01, FiscalAI reports. The firm had revenue of $4.73 million for the quarter, compared to analysts’ expectations of $4.45 million. Nephros had a net margin of 8.26% and a return on equity of 15.81%.

Nephros Trading Down 3.3%

Shares of NASDAQ:NEPH traded down $0.13 during midday trading on Thursday, reaching $3.80. 21,369 shares of the company were exchanged, compared to its average volume of 45,460. The stock has a market cap of $40.38 million, a PE ratio of 29.23 and a beta of 1.42. The business’s fifty day moving average is $4.28 and its two-hundred day moving average is $4.65. Nephros has a one year low of $1.49 and a one year high of $6.42.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Nephros in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $6.00.

Institutional Trading of Nephros

Several hedge funds have recently modified their holdings of NEPH. Kestra Advisory Services LLC purchased a new stake in Nephros during the fourth quarter valued at $29,000. Dimensional Fund Advisors LP bought a new stake in shares of Nephros in the 3rd quarter worth about $64,000. Heron Bay Capital Management purchased a new stake in shares of Nephros during the 4th quarter valued at about $66,000. Citadel Advisors LLC raised its position in shares of Nephros by 39.2% during the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after buying an additional 4,655 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after acquiring an additional 7,062 shares during the last quarter. 41.10% of the stock is owned by hedge funds and other institutional investors.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.